HEALTH COVERAGE, INSURANCE AND FINANCIAL SERVICES

Reproduced and distributed under the direction of the Clerk of the House.

STATE OF MAINE

HOUSE OF REPRESENTATIVES

130TH LEGISLATURE

FIRST SPECIAL SESSION

COMMITTEE AMENDMENT “ ” to H.P. 7, L.D. 41, “Resolve, Regarding Legislative Review of Portions of Chapter 570: Uniform Reporting System for Prescription Drug Price Data Sets, a Major Substantive Rule of the Maine Health Data Organization”

Amend the resolve by striking out all of section 1 and inserting the following:

'Sec. 1. Adoption. Resolved: That final adoption of portions of Chapter 570: Uniform Reporting System for Prescription Drug Price Data Sets, a provisionally adopted major substantive rule of the Maine Health Data Organization that has been submitted to the Legislature for review pursuant to the Maine Revised Statutes, Title 5, chapter 375, subchapter 2-A, is authorized only if the following changes are made:

1. The rule must be amended in Section 1(C) to remove the definition of "drug product family";

2. The rule must be amended in Section 2(C) to remove the requirement that the Maine Health Data Organization identify a list of drug product families for which it intends to request pricing component data from reporting entities and require the submission of pricing component data for each drug product family; and

3. The rule must be amended to remove all references to "drug product family."'

Amend the resolve by relettering or renumbering any nonconsecutive Part letter or section number to read consecutively.

SUMMARY

This amendment, which is the minority report of the committee, authorizes final adoption of portions of Chapter 570: Uniform Reporting System for Prescription Drug Price Data Sets, a major substantive rule of the Maine Health Data Organization only if the rule is amended to remove the definition of "drug product family" and the requirement that the Maine Health Data Organization identify a list of drug product families for which it
COMMITTEE AMENDMENT “ ” to H.P. 7, L.D. 41

1 intends to request pricing component data from reporting entities and require the
2 submission of pricing component data for each drug product family.